Indoco Remedies Baddi Facility Receives EU GMP Certification from Malta Medicines Authority
Indoco Remedies' Baddi Unit I manufacturing facility has received EU GMP certification from the Malta Medicines Authority after an inspection from January 29 to February 3, 2026. Managing Director Aditi Panandikar stated this reflects the company's commitment to quality and global standards.
The EU GMP certification enhances the company's credibility and market access in regulated markets, positively impacting its business operations and growth prospects.
The company received a crucial EU GMP certification, which is a positive development for its manufacturing capabilities and global market access.
Indoco Remedies Limited announced that its manufacturing facility for solid oral dosage form (Unit I) located in Baddi underwent an inspection by the Malta Medicines Authority from January 29, 2026, to February 3, 2026.
The facility has successfully obtained EU GMP certification from the Malta Medicines Authority, confirming its compliance with Good Manufacturing Practice requirements as stipulated in the EC Directive.
Ms. Aditi Panandikar, Managing Director of Indoco Remedies Ltd., commented, "This approval from the Malta Medicine Authority further reflects Indoco’s strong commitment to quality, compliance, and adherence to global regulatory standards. We are focused on maintaining the highest quality standards while catering to our customers in India and globally."
Indoco Remedies Limited is a fully integrated, research-oriented pharmaceutical company with a global presence, reporting a turnover of US$175 million (approximately ₹1450 crore) and employing over 6000 people. The company operates 10 manufacturing facilities (6 for FDFs and 4 for APIs) approved by major regulatory authorities, including the USFDA and UK-MHRA.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.